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This paper serves to update previously published guidance
on rationale and methodology for HER2 laboratory testing
following the recommendation for the use of HER2 targeted
treatment in the management of advanced breast cancer in
the UK. Emphasis is placed on the standardisation of
methodology and assessment and strategies to achieve
high quality performance. A two phase testing algorithm
based on first line immunocytochemistry evaluation and
second line fluorescence in situ hybridisation assessment of
borderline cases is recommended. To ensure maintenance
of expertise, an annual caseload volume of at least 250
cases is recommended for laboratories providing a testing
service.
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T
he humanised anti-HER-2/neu (also known
as c-erbB-2, further denoted HER2) mono-
clonal antibody trastuzumab (Herceptin),1
has recently been endorsed by the UK National
Institute for Clinical Excellence (NICE) for the
treatment of metastatic disease,2 (fig 1) and
establishing tumour HER2 status is a prerequi-
site for the use of trastuzumab.1 2 These guide-
lines update the previous UK HER2 testing
guidelines,3 and have been formulated to give
advice on methodology and quality assurance for
local testing to ensure that HER2 testing results
are accurate and reliable, regardless of the test
that is used. Authorship is based on representa-
tion of existing UK groups with experience in
HER2 assay methodology and performance,
quality assurance, guideline production, and
establishing performance standards. These
guidelines aim to offer guidance to those
laboratories that are considering offering an
HER2 evaluation service, provide information
on internal and external quality assurance, and
provide a basis for establishing service standards
for use by professional and National Health
Service groups in the UK. NICE has referred to
the need to adhere to our published guidelines
and this document serves to update the existing
guidance.
‘‘These guidelines update the previous UK
HER2 testing guidelines, and have been
formulated to give advice on methodology
and quality assurance for local testing to
ensure that HER2 testing results are accurate
and reliable, regardless of the test that is
used’’
GENERAL PRINCIPLES
Suitable samples
Formalin fixed, paraffin wax embedded tumour
tissue samples are appropriate for assay.4–9
Ideally, buffered formalin should be used for
fixation because the use of Bouin’s fixative will
preclude testing by fluorescence in situ based
methods. Other methods of tissue fixation can
also adversely affect antigen reactivity.
Caseload
N Laboratories providing a testing service should
be carrying out a minimum of 250 assays each
year for immunohistochemical detection of
HER2. This target value has been set to ensure
continuing expertise of assay providers. There
is evidence of higher consistency of assay
quality when tests are performed by high
volume reference laboratories.10 11 Specifically,
laboratories with low volumes using immu-
nohistochemistry (IHC) have higher frequen-
cies of IHC positive cases and reduced levels of
IHC/FISH (fluorescence in situ hybridisation)
concordance, which is related to a higher pro-
portion of IHC positive/FISH negative results.
N Centres with low numbers of cases (, 250/
year) requiring IHC assay should consider
using a reference laboratory service.
N Similar principles apply to FISH testing and it
is recommended that laboratories testing
fewer than 100 cases each year should
consider referring their workload to a refer-
ence laboratory. A smaller caseload has been
set for the FISH assay because it is generally
accepted to be a more discriminant test at the
positive negative borderline, has greater ease
of methodological standardisation, and less
observer variation
Appropriate laboratory assay methods
IHC and FISH5–9 are the techniques recommended
for determining HER2 status. Currently, the
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other available HER2 testing techniques (chromogenic in
situ hybridisation, polymerase chain reaction, enzyme
linked immunosorbent assay, and Southern blotting)
should be used for research only.
For both immunohistochemical and FISH based HER2
testing, comprehensive standardisation of methodology,
including monitoring of scoring procedures, and the inclu-
sion of validated controls, is mandatory. In the UK,
participation and satisfactory performance in the current
NEQAS scheme for IHC and the forthcoming NEQAS scheme
for HER2 FISH is a requirement. These schemes are open to
laboratories across Europe. Although published data support
the use of FISH for the selection of patients most likely to
respond to trastuzumab, the current UK licence for this agent
allows the treatment of patients with tumours strongly
staining by IHC. Worldwide, there remains an ongoing
debate as to whether laboratories should switch to the use
of FISH for all specimens, removing the need for a second tier
of testing to identify HER2 positive cases, or adopt the two
tier testing strategy (fig 2) currently in use in the UK
reference laboratories. Current experience from the UK
reference laboratories indicates that there is a very high level
of correlation between IHC and FISH assay results in the 0/1+
and 3+ IHC categories, negating the need for dual IHC and
FISH based assays in most cases12; however, other published
studies show higher rates of discordance in these categories.
Caution may be needed before extrapolating the experience
of the reference centres to laboratories with lower case loads,
and laboratories are strongly advised to consider an initial
validation testing phase to confirm high levels of concor-
dance between IHC and FISH for IHC 0/1+ cases and 3+ cases.
Although the UK licence remains focused on IHC positivity
it is logical, in the light of such data, to use FISH as a
secondary test in the equivocal 2+ IHC category to clarify the
HER2 status of these cases (fig 2); however, once trastuzu-
mab is licensed for both FISH and IHC positive cases it is
possible that any advantage of the current two tier testing
system will be scrutinised. In this case, as at present in other
counties, some laboratories will choose to use FISH as a front
line diagnostic test without the use of IHC. It is also expected
that emerging data on accuracy of prediction of response to
HER2 targeted treatments will influence the choice of testing
method.
In summary, current UK recommendations are for a two
tier testing strategy, using the model show in fig 2, but this
does not preclude laboratories from using primary FISH
testing once there is drug licence revision of trastuzumab to
include FISH positive status as an indication for treatment.
Controls
The inclusion of controls and their detailed scrutiny are
essential to ensure test accuracy. A recommended positive
control or controls producing results close to important
decision making points and a negative control are recom-
mended.
Cell line preparations containing multiple samples of
known HER2 status characterised by FISH and IHC are
useful as controls.13 Where possible, tissue based controls,
preferably from breast cancers, should also be used in all
assay runs.
Excessive antigen retrieval can be monitored by an
evaluation of normal breast epithelial cells as an internal
control. Should membrane reactivity be identified in the
normal cell population, excessive antigen retrieval may have
occurred and retesting of the entire run should be considered.
It is preferable to titrate the staining methodology to avoid
detecting normal degrees of HER2 expression, rather than
advocate a scoring system based on subtracting the degree of
staining seen in normal cells from tumour cell staining.
Evaluation
For the assessment of both IHC and FISH preparations
training and experience in the interpretation of histological
characteristics of breast tissue are essential. The recognition
of different histological tumour types is required. In
particular, the HER2 status should be determined only on
the invasive portion of the tumour and IHC positivity or FISH
amplification should not be reported as a positive result in
isolation. Image analysis systems are currently under
investigation and may provide alternatives to manual scoring
for both IHC and FISH in the future; however, at present,
insufficient evidence is available to recommend their routine
use in the diagnostic setting.
IMMUNOHISTOCHEMISTRY
For all IHC tests
Antigen retrieval processes are crucial; they must be
standardised and follow strict protocols. The antibody used
and its titre should be predefined. Standardisation can be
NICE summary statement
The clinical effectiveness and cost effectiveness of trastuzumab for the
treatment of advanced breast cancer
1 Guidance
1.1 Trastuzumab in combination with paclitaxel (combination trastuzumab is
currently only licensed for use with paclitaxel) is recommended as an
option for people with tumours expressing human epidermal growth 
factor receptor 2 (HER2) scored at levels of 3+ who have not received
chemotherapy for metastatic breast cancer and in whom anthracycline 
treatment is inappropriate
1.2 Trastuzumab monotherapy is recommended as an option for people with
tumours expressing HER2 scored at levels of 3+ who have received at 
least two chemotherapy regimens for metastatic breast cancer. Prior 
chemotherapy must have included at least an anthracycline and a taxane
where these treatments are appropriate. It should also have included
hormonal therapy in suitable oestrogen receptor positive patients
1.3 HER2 levels should be scored using validated immunohistochemical
techniques and in accordance with published guidelines. Laboratories
offering tissue sample immunocytochemical or other predictive tests for
treatment response should use validated standardised assay methods and
participate in and demonstrate satisfactory performance in a recognised
external quality assurance scheme
Figure 1 Updated National Institute for Clinical Excellence (NICE)
recommendations for the treatment of metastatic disease by trastuzumab
(Herceptin).
IHC score
Score 3+
Positive
IHC score
2+
Borderline
Standardised, validated IHC assay
For
FISH assay
FISH ratio >2.0
Amplified
Positive
FISH ratio <2.0
Not amplified
Negative
IHC score
0 and 1+
Negative
Figure 2 Recommended testing algorithm. FISH, fluorescence in situ
hybridisation; IHC, immunohistochemistry.
234 Ellis, Bartlett, Dowsett, et al
www.jclinpath.com
achieved using commercial assay systems such as the
Herceptest (DakoCytomation, Ely, Cambridgeshire, UK). For
in house assays no single antibody has consistently been
shown to be superior in terms of specificity and sensitivity. At
present, antibody clones CB11 (Novocastra, Newcastle upon
Tyne, UK), TAB 250 (Zymed, San Francisco, California, USA),
and polyclonal anti-sera AO485 (DakoCytomation) are the
most widely used for all assay methods. Test conditions
(temperature, exposure time, etc) should be standardised. To
achieve good concordance between IHC and FISH assays it is
recommended that the sensitivity of the IHC method should
be set below that which detects normal amounts of HER2
protein in benign or normal breast epithelial cells.
Validation of standardised assay method
Test conditions should be optimised so that distinct moderate
or strong membrane staining identifies FISH positive
samples. This can be achieved by:
(1) Dual IHC and FISH assay of a contemporary series of
breast carcinomas (minimum 100 cases). FISH can be
confined to those cases demonstrating some evidence of
membrane reactivity (1, 2, or 3+).
(2) Laboratories can use a series of recent cases from their
own hospital. Alternatively, the use of tumour tissue array
blocks for validation may reduce costs. It may be possible to
obtain such sections, which have already been scored for IHC
and FISH, from a research laboratory or reference source.
(3) Laboratories should aim to achieve high degrees of
concordance between IHC 0/1+ results and FISH negativity
and between IHC 3+ results and FISH positivity.
Laboratories not wishing to standardise in house method-
ology should consider using a commercial kit assay system
such as the Herceptest (DakoCytomation).
Scoring IHC
Only membrane staining of the invasive tumour should be
considered when scoring IHC tests. If a commercial kit assay
system is used, it is recommended that laboratories adhere
strictly to the kit assay protocol and scoring methodology.
Local modifications of techniques can lead to false positive
and negative assay results. The scoring method recom-
mended is a semiquantitative system based on the intensity
of the reaction product and the percentage of membrane
positive cells, giving a score range of 0 to 3+ (fig 3). Samples
scoring 3+ are regarded as unequivocally positive and 0/1+ as
negative. Borderline 2+ samples require confirmation using
another analysis system, ideally FISH (fig 2). Some commer-
cial providers of kit assay systems provide detailed guidance
on scoring IHC assays, which can help observers to avoid
pitfalls and problems. Observers should be aware of the range
of common artefacts, including edge artefacts, which can be
problematic in small biopsy samples, and the effects of
variation in method sensitivity, such as excessive antigen
retrieval, leading to background staining and normal cell
membrane reactivity.
‘‘Only membrane staining of the invasive tumour should
be considered when scoring immunohistochemistry tests’’
Non-commercial kit assay methods can be scored on a
similar basis or by modification to a three tier system of
positive, borderline, and negative. Until better evidence on
scoring methodology emerges, the cutoff points for such
simplified assay scoring systems should be based on the
existing HercepTest kit method, with a positive score being
based on a 3+ score, borderline on a 2+ score, and negative a
1+ or 0 score (figs 2 and 3).
Interobserver variation in the assessment of staining can
lead to misclassification of HER2 status.14 Each individual
assessor should standardise scoring against known positive,
negative, and borderline cases. It is also preferable to assess
comparability of scoring with a colleague on a regular basis.
Quality assurance
All clinical laboratories using assays for HER2 as predictive or
prognostic tests must participate in an appropriate external
quality assurance (EQA) programme, such as that run by the
United Kingdom National External Quality Assessment
Scheme for Immunocytochemistry (UK NEQAS-ICC).
On a quarterly basis, UK NEQAS-ICC circulates unstained
sections from a formalin fixed and paraffin wax processed
block comprising human breast carcinoma cell lines (MDA-
MB-453, BT-20, and MCF-7) and an ovarian carcinoma cell
line (SKOV-3) to over 100 laboratories. Previous FISH
analysis on these cell lines has shown the SKOV-3 and
MDA-MB-453 cell lines to have HER2 gene amplification,
whereas the BT-20 and MCF-7 cell lines do not.13 When the
sensitivity of the assay is appropriate, the cell line SKOV-3
should be unequivocally positive (3+) and the cell lines MCF-
7 and BT-20 should be unequivocally negative (0 or 1+). The
most appropriate result on the cell line MDA-MB-453 is 2+.
Following strict adherence to the Dako HercepTest staining
protocol, it has been shown that over 80% of laboratories
using the HercepTest achieve this permutation of immuno-
staining on the cell lines SKOV-3, MDA-MB-453, BT-20, and
MCF-7. Laboratories using individually customised assays
utilising the CB11 and TAB 250 clones and DAKO polyclonal
antisera have achieved equivalent staining.
Participating laboratories are requested to test the UK
NEQAS sections and their own in house control for HER2 and
to return them to the organising centre for evaluation by a
panel of five expert assessors using the method of evaluation
initially devised for the Herceptin clinical trials assay, with
the median value from the five assessors being taken as the
final score.13–15
To identify and rectify suboptimal performance for HER2
assays by UK laboratories within an acceptable time frame,
UK NEQAS-ICC will approach all UK laboratories achieving
an inappropriate result on the UK NEQAS sections (a score
other than 3+, 2+, 0/1+, 0/1+ on the cell lines SKOV-3,
MDA-MB-453, BT-20, and MCF-7, respectively) and provideFigure 3 Recommended immunohistochemistry scoring method.
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advice for improvement. Any of these participants subse-
quently achieving an inappropriate result at two subsequent
assessment runs on the UK NEQAS sections will be issued a
warning letter. With the issue of this warning letter, UK
NEQAS will provide further technical advice and support,
including attendance at the UK NEQAS organisers’ labora-
tory by biomedical scientists from the poor performing
laboratory. All attempts will be made to assist the laboratory
to improve. However, failure to do so, with the laboratory
accruing a total of four successive inappropriate scores
on the UK NEQAS sections, despite intensive advice and
assistance, will result in the laboratory concerned being
removed from the UK NEQAS for HER2 scheme register and
being reported to the chairman of the National Quality
Assurance Advisory Panel (NQAAP). This may ultimately
result in the laboratory concerned losing its CPA status for
this test. However, the laboratory will be permitted to
continue participating in EQA for HER2 (if it so wishes)
and the chairman of NQAAP will be notified if it is able to
show significant improvement by subsequently accruing
acceptable results at all of four successive assessment runs.
This approach will ensure that poorly performing laboratories
are identified promptly and the situation rectified through
appropriate action being taken within a 12 month period,
either by the laboratories showing improvement to an
acceptable standard or by being removed from the UK
NEQAS participation register and loosing their accreditation
status for this test.
FLUORESCENCE IN SITU HYBRIDISATION (FISH)
FISH testing for HER2 should meet the following criteria:
(1) Comprehensive standardisation of methodology.
(2) Validated controls. The inclusion of a chromosome 17
control to allow for correction of the HER2 signal number for
chromosome 17 aneusomy (seen in over 50% of cases) is
considered beneficial by many laboratories and is recom-
mended.
(3) Validated scoring procedures.
General principles
There is no evidence that storage of blocks or slides leads to
the deterioration of signal. However, it is recommended that
storage of cut sections from controls or samples for over six to
12 months should be avoided.
It is advisable to locate areas of invasive tumour using a
serial section stained with haematoxylin and eosin and to use
this to locate tumour areas to be scored after testing. Care
should be taken to avoid areas of ductal carcinoma in situ,
which can show amplification even when adjacent invasive
tumour cells are negative. With experience, such features can
be identified under fluorescence microscopy; however, the
use of serial haematoxylin and eosin sections is essential
should there be any uncertainty in this area.
Tissue digestion should be standardised to maintain
nuclear morphology and should follow strict protocols.16
Some laboratories find it helpful to evaluate nuclear structure
before hybridisation and adjust digestion, where appropriate,
to preserve nuclear integrity. This may be particularly
valuable with difficult sections, cytology samples, bone
biopsies, etc. Evaluation of sections before hybridisation can
also improve efficiency and is recommended. Hybridisation
and washing steps should be standardised. Guidance can be
provided by the reference laboratories. Use of automated
tissue processors and standardised commercial tissue diges-
tion kits can improve consistency and should be considered.
It is recommended that commercially available probes are
used. For systems using in house nick translated probes,
attention should be given to batch variability of nick
translation enzymes, and other reagents.
Laboratories not wishing to use in house methods should
consider using a commercial system such as Vysis PathVysion
(Abbott UK, Queensborough, Kent, UK). Other commercial
systems currently available are not yet widely validated or
lack the chromosome 17 control discussed above.
Scoring FISH
HER2 FISH testing results are conventionally expressed as
the ratio of HER2 signal to chromosome 17 signal. Tumours
showing a ratio of more than 2 should be considered positive.
Cut off values for HER2 gene amplification when chromo-
some 17 probes are not used have not been established.
‘‘Published data suggest that interobserver variation is
significantly lower for fluorescence in situ hybridisation
than for immunohistochemistry’’
The number of chromosome 17 and HER2 signals is scored
for between 20 and 60 cells where possible, using at least
three distinct tumour fields, and the mean HER2 to
chromosome 17 copy ratio is calculated. In most cases,
where either clear amplification is observed or the ratio is
below 1.5, scoring of 20 cells is sufficient. In cases where
either tumour heterogeneity is seen (1–2% of cases) or the
ratio is close to 2.0 (between 1.5 and 2.3) more cells should be
scored (up to 60). Samples with more than 2.0 copies of
HER2 for each chromosome 17 are considered to be
amplified. Published data suggest that interobserver variation
is significantly lower for FISH than for IHC.17 In this study,
interobserver variations for both FISH and IHC analyses were
evaluated on the same patient cohort, and, as measured by k
statistics, were lower for two IHC based tests (0.67 and 0.74)
than for FISH testing (0.973; 17). Using IHC based testing,
concordance between two observers in selecting patients for
0/1+ v 2/3+ intensity was seen in 81% of cases, whereas for
FISH, concordance in the identification of amplified and non-
amplified cases was greater than 99%.17 Further data on
reproducibility of IHC and FISH scoring are reviewed
elsewhere.18 19 However, especially when developing a new
service, care needs to be taken. The recommendation is that
laboratories should perform validation studies by dual
observer scoring when training new staff until interobserver
variation for normal specimens and those with low level
amplification is routinely below 15%. Continued monitoring
of scoring offers advantages in quality control and training
but is not a requirement. Variation increases with highly
amplified samples, and is not crucial where the ratio exceeds
4.
Quality assurance
To ensure adequate quality assurance, UK laboratories
wishing to set up independent FISH testing are recom-
mended to join the proposed EQA scheme coordinated by
NEQAS. Currently we envisage using tissue microarrays or
multiblocks to provide adequate material for analysis. The
scheme will be designed to evaluate methodological and
scoring aspects but may not cover morphological aspects.
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